Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04802395 · ClinicalTrials.gov registry record
Real World Evidence Clinical Utility Study of KidneyIntelX
A clinical trial of Chronic Kidney Diseases and Diabetic Kidney Disease, sponsored by Renalytix AI.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT04802395: Recruiting study of Chronic Kidney Diseases and Diabetic Kidney Disease, sponsored by Renalytix AI.
NCT04802395 is a study of Chronic Kidney Diseases and Diabetic Kidney Disease that is actively recruiting participants, run by Renalytix AI. The registered enrollment target is 10,000 participants, above the 308-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (3147% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04802395, a study of Chronic Kidney Diseases and Diabetic Kidney Disease, is actively recruiting participants, sponsored by Renalytix AI.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
Primary Outcome
Proportion (target: 20%) of patients referred to a dietician, diabetologist, or nephrologist.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST KidneyIntelX
Study Locations (1)
New York
- Mount Sinai Health System - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2026-12-01 |
What NCT04802395 shows while recruiting
NCT04802395 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 308-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (3147% higher).
The record links to 2 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which KidneyIntelX is the first listed.
NCT04802395 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04802395 about?
NCT04802395 is a clinical study titled "Real World Evidence Clinical Utility Study of KidneyIntelX". The purpose of this study is to assess the impact of the KidneyIntelX assay utilized as part of the current standard of care on the management of patients seen in the primary care physician's office at Mount Sinai.
What is the current status of trial NCT04802395?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 2021-03-02. Estimated completion is 2026-12-01.
What conditions does trial NCT04802395 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Diabetic Kidney Disease.
What interventions are being tested in trial NCT04802395?
The interventions under investigation include: KidneyIntelX (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04802395?
This trial is sponsored by Renalytix AI, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04802395 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04802395's enrollment target sits among peer trials
10,000 1st of 73 higher than 73 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Mindfulness in Chronic Kidney Disease
RECRUITING · NA
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI